カテゴリ： GlobalData, ドイツ, 企業調査

Bayer AG (BAYN)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Bayer AG (BAYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012253
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：174
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Bayer AG (Bayer) carries out the research, development, production and commercialization of products in the areas of human and animal health care, and agriculture. It provides pharmaceuticals for cardiology, women’s healthcare, oncology, hematology, ophthalmology, infection and other indications. The company’s product portfolio includes prescription products, specialty therapeutics, animal health care products, diagnostic imaging equipment, nonprescription (over-the-counter – OTC) products, seeds, crop protection solutions, nonagricultural pest control solutions, and high-tech polymer materials. Bayer markets its healthcare and crop protection products principally through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, the US, and other markets such as Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, Germany.

Bayer AG (BAYN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Bayer AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Bayer AG, Medical Devices Deals, 2011 to YTD 2017 13
Bayer AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Bayer AG, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 19
Venture Financing 21
BlueRock Therapeutics Raises USD225 Million in Series A Financing 21
Private Equity 22
Bayer May Sell Dermatology Business 22
Sobera Capital Acquires Minority Stakes In Biopharma Companies From Bayer Pharma And Bayer HealthCare 23
Partnerships 24
ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 24
Bayer and PeptiDream Enter into Partnership 25
Bayer Enters into Co-Development Agreement with Loxo Oncology 26
Bayer and Vanderbilt University Medical Center Enter into Research Agreement 27
leadXpro Enters into Agreement with Bayer 28
University of Pittsburgh and Bayer Form Research Collaboration Agreement 29
Bayer Enters into Partnership with Evotec 30
Bayer Enters into Agreement with National Surgical Adjuvant Breast and Bowel Project 31
Bayer Enters into Co-Development Agreement with Regeneron Pharma 32
Bayer and CRISPR Therapeutics Forms Joint Venture 33
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 34
Proteros Biostructures Enters into Research Agreement with Bayer 35
Bayer HealthCare Enters Co-Development Agreement with University of Oxford 36
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 37
arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 38
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 39
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 40
Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 41
Bayer Enters Into Co-Marketing Agreement With Ildong Pharma For OTC Drugs 42
Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 43
X-Chem and Bayer Pharma Expand Agreement 44
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 45
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 46
Algeta Exercises Option Agreement With Bayer To Co-Promote Alpharadin 48
Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 49
Bayer HealthCare Pharma Enters Into Research Agreement With Ludwig Boltzmann Institute 50
MediSapiens Enters Into Co-Development Agreement With Bayer HealthCare Pharma 51
Bayer Enters Into Joint Venture Agreement With Yunona Holdings 52
Dong-A Pharma Enters Into Co-Marketing Agreement With Bayer Korea 53
Bayer Schering Pharma Enters Into Research Agreement With University of California, San Francisco 54
Licensing Agreements 55
Bayer Enters into Licensing Agreement with Progenics Pharma 55
Taisho Pharma Enters into Licensing Agreement with Bayer Yakuhin 56
Bayer Enters into Licensing Agreement with ERS Genomics 57
X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 58
Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 59
BioInvent Extends Licensing Agreement With Bayer Pharma 60
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 61
Oxford Pharmascience Enters Into Licensing Agreement With Bayer Consumer Care 62
Lead Discovery Enters Into Licensing Agreement With Bayer Schering 63
Equity Offering 64
Crispr Therapeutics Prices Private Placement of Shares for USD35 Million 64
Debt Offering 65
Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 65
Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 66
Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 67
Bayer Raises USD1.5 Billion in Public Offering of 3% Bonds Due 2021 68
Bayer Raises USD400 Million in Public Offering of Bonds Due 2017 69
Bayer Raises USD500 Million in Public Offering of Notes Due 2016 70
Bayer Raises USD2 Billion in Public Offering of 2.375% Bonds Due 2019 71
Bayer Raises USD1.75 Billion in Public Offering of 3.375% Bonds Due 2024 72
Bayer Raises USD850 Million in Public Offering of 1.5% Bonds Due 2017 73
Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 74
Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 76
Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 78
Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 79
Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 80
Bayer Completes Public Offering Of Notes Due 2019 For US$102 Million 81
Bayer Completes Public Offering Of Notes Due 2016 For US$259 Million 82
Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For US$363 Million 83
Asset Transactions 84
Famar Health Care Services Acquires Pointe-Claire Manufacturing Site from Bayer 84
WellSpring Pharma Acquires Bactine 85
Alvogen Acquires Five Hormonal Products from Bayer Pharma 86
Bayer Korea to Sell Mercilon 87
Alliance Pharma Acquires Rights To Irenat From Bayer 88
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For US$4.8 Million 89
Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 90
Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 91
Acquisition 92
Bayer to Acquire Monsanto for USD66 Billion 92
Bayer to Acquire Minority Stake in CRISPR Therapeutics for USD35 Million 94
Bayer Acquires Dihon Pharma for USD586 Million 95
Bayer Nordic Completes Acquisition Of Algeta For US$2.58 Billion 96
Bayer Completes Acquisition Of Steigerwald Arzneimittelwerk, Herbal Treatments Provider 98
Bayer Completes Acquisition Of 96.4% Stake In Conceptus For US$1.1 Billion 99
Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 101
Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 102
SuperGen Completes Acquisition Of Astex Therapeutics 103
Bayer AG – Key Competitors 106
Bayer AG – Key Employees 107
Bayer AG – Locations And Subsidiaries 110
Head Office 110
Other Locations & Subsidiaries 110
Joint Venture 118
Recent Developments 120
Strategy And Business Planning 120
Sep 20, 2016: Bayer sets ambitious growth and earnings aspirations 120
Financial Announcements 122
Oct 26, 2017: Bayer: Sales and earnings increased 122
Apr 27, 2017: Strong start to the year for Bayer 127
Apr 26, 2016: Bayer Announces Interim report for the first quarter of 2016 130
Corporate Communications 132
Nov 15, 2017: Heiko Schipper is the new CEO and Head of the Consumer Health Division at Bayer 132
Sep 29, 2017: Bayer helping people affected by the earthquake in Mexico 133
Sep 12, 2017: Wolfgang Nickl to be new Chief Financial Officer at Bayer 134
Apr 27, 2017: Supervisory Board of Bayer extends service contract of CFO Johannes Dietsch to the end of May 2018 135
Jan 17, 2017: Dr. Carsten Brunn to Lead Bayer’s Pharmaceuticals Business in the Americas Region 136
Oct 17, 2016: Bayer Early Excellence in Science Award 2016: EUR 30,000 for international research scientists 137
Apr 25, 2016: 2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner 139
Feb 24, 2016: Werner Baumann to succeed Dr. Marijn Dekkers as Chairman of the Board of Management of Bayer AG 140
Legal and Regulatory 141
Aug 22, 2017: Bayer will continue to work constructively with the European Commission 141
Government and Public Interest 142
Jul 11, 2017: Bayer Awards $2 Million in Grants to Advance Hemophilia Research and Patient Care 142
Feb 22, 2017: Another record year for Bayer – good progress with the acquisition of Monsanto 143
Nov 13, 2016: New landmark study reveals adults with diabetes at unnecessary risk of vision loss 147
May 12, 2016: Bayer: B vitamins – an effective team for mood and brain activity 149
Feb 25, 2016: Another record year for Bayer 150
Product News 153
Aug 10, 2016: Bayer: Prevalence of life-threatening neural tube defects on the rise 153
07/21/2016: Sorafenib treatment alters immunosuppressive phenotypes in hepatocellular carcinoma 154
02/03/2016: NICE issues full guidance for Xofigoq (radium-223 dichloride) 155
01/27/2016: NICE recommends radium 223 dichloride for prostate cancer 156
01/04/2016: Bayer Presents Latest Xofigo (radium Ra 223 dichloride) Injection Research at ASCO GU 2016 157
Product Approvals 158
Mar 29, 2016: Bayer Receives Approval for Xofigo in Japan 158
Clinical Trials 159
Jul 24, 2017: Evotec and Bayer Advance Endometriosis Programme into Phase I Clinical Development and Extend Alliance 159
Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 160
Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 161
May 19, 2016: Bayer to Showcase Anetumab Ravtansine at ASCO 2016 162
May 19, 2016: Bayer to Showcase Latest data on Nexavar (sorafenib) at ASCO 2016 163
May 18, 2016: Bayer to Showcase Latest Data on Xofigo (radium Ra 223 dichloride) at ASCO 2016 164
Mar 07, 2016: Major Liver Cancer Study Completes Palliative Cohort Enrolment 166
Jan 26, 2016: ImmunoGen Earns Milestone with Bayer’s Initiation of a Phase 2 Clinical Study Designed to Support Anetumab Ravtansine Registration 167
Other Significant Developments 168
Dec 01, 2017: Bayer invests in differentiated drug pipeline with over 50 projects focused on high unmet medical needs 168
Jul 27, 2016: Bayer raises sales and earnings 171
Appendix 174
Methodology 174
About GlobalData 174
Contact Us 174
Disclaimer 174

List of Tables
Bayer AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Bayer AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Bayer AG, Deals By Therapy Area, 2011 to YTD 2017 11
Bayer AG, Medical Devices Deals, 2011 to YTD 2017 13
Bayer AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 19
BlueRock Therapeutics Raises USD225 Million in Series A Financing 21
Bayer May Sell Dermatology Business 22
Sobera Capital Acquires Minority Stakes In Biopharma Companies From Bayer Pharma And Bayer HealthCare 23
ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 24
Bayer and PeptiDream Enter into Partnership 25
Bayer Enters into Co-Development Agreement with Loxo Oncology 26
Bayer and Vanderbilt University Medical Center Enter into Research Agreement 27
leadXpro Enters into Agreement with Bayer 28
University of Pittsburgh and Bayer Form Research Collaboration Agreement 29
Bayer Enters into Partnership with Evotec 30
Bayer Enters into Agreement with National Surgical Adjuvant Breast and Bowel Project 31
Bayer Enters into Co-Development Agreement with Regeneron Pharma 32
Bayer and CRISPR Therapeutics Forms Joint Venture 33
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 34
Proteros Biostructures Enters into Research Agreement with Bayer 35
Bayer HealthCare Enters Co-Development Agreement with University of Oxford 36
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 37
arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 38
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 39
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 40
Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 41
Bayer Enters Into Co-Marketing Agreement With Ildong Pharma For OTC Drugs 42
Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 43
X-Chem and Bayer Pharma Expand Agreement 44
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 45
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 46
Algeta Exercises Option Agreement With Bayer To Co-Promote Alpharadin 48
Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 49
Bayer HealthCare Pharma Enters Into Research Agreement With Ludwig Boltzmann Institute 50
MediSapiens Enters Into Co-Development Agreement With Bayer HealthCare Pharma 51
Bayer Enters Into Joint Venture Agreement With Yunona Holdings 52
Dong-A Pharma Enters Into Co-Marketing Agreement With Bayer Korea 53
Bayer Schering Pharma Enters Into Research Agreement With University of California, San Francisco 54
Bayer Enters into Licensing Agreement with Progenics Pharma 55
Taisho Pharma Enters into Licensing Agreement with Bayer Yakuhin 56
Bayer Enters into Licensing Agreement with ERS Genomics 57
X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 58
Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 59
BioInvent Extends Licensing Agreement With Bayer Pharma 60
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 61
Oxford Pharmascience Enters Into Licensing Agreement With Bayer Consumer Care 62
Lead Discovery Enters Into Licensing Agreement With Bayer Schering 63
Crispr Therapeutics Prices Private Placement of Shares for USD35 Million 64
Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 65
Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 66
Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 67
Bayer Raises USD1.5 Billion in Public Offering of 3% Bonds Due 2021 68
Bayer Raises USD400 Million in Public Offering of Bonds Due 2017 69
Bayer Raises USD500 Million in Public Offering of Notes Due 2016 70
Bayer Raises USD2 Billion in Public Offering of 2.375% Bonds Due 2019 71
Bayer Raises USD1.75 Billion in Public Offering of 3.375% Bonds Due 2024 72
Bayer Raises USD850 Million in Public Offering of 1.5% Bonds Due 2017 73
Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 74
Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 76
Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 78
Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 79
Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 80
Bayer Completes Public Offering Of Notes Due 2019 For US$102 Million 81
Bayer Completes Public Offering Of Notes Due 2016 For US$259 Million 82
Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For US$363 Million 83
Famar Health Care Services Acquires Pointe-Claire Manufacturing Site from Bayer 84
WellSpring Pharma Acquires Bactine 85
Alvogen Acquires Five Hormonal Products from Bayer Pharma 86
Bayer Korea to Sell Mercilon 87
Alliance Pharma Acquires Rights To Irenat From Bayer 88
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For US$4.8 Million 89
Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 90
Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 91
Bayer to Acquire Monsanto for USD66 Billion 92
Bayer to Acquire Minority Stake in CRISPR Therapeutics for USD35 Million 94
Bayer Acquires Dihon Pharma for USD586 Million 95
Bayer Nordic Completes Acquisition Of Algeta For US$2.58 Billion 96
Bayer Completes Acquisition Of Steigerwald Arzneimittelwerk, Herbal Treatments Provider 98
Bayer Completes Acquisition Of 96.4% Stake In Conceptus For US$1.1 Billion 99
Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 101
Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 102
SuperGen Completes Acquisition Of Astex Therapeutics 103
Bayer AG, Key Competitors 106
Bayer AG, Key Employees 107
Bayer AG, Subsidiaries 110
Bayer AG, Joint Venture 118

★海外企業調査レポート[Bayer AG (BAYN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Mevion Medical Systems Inc：医療機器：M&Aディール及び事業提携情報
    Summary Mevion Medical Systems Inc (Mevion), formerly Still River Systems is a medical equipment company that offers therapy systems. The company offers radiation therapy and proton therapy systems for the treatment of cancer. It provides MEVION S250 proton therapy system designed for preserving tre …
  • Hovnanian Enterprises, Inc.：企業の戦略・SWOT・財務情報
    Hovnanian Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hovnanian Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Biogen Inc (BIIB)：医療機器：M&Aディール及び事業提携情報
    Summary Biogen Inc (Biogen) is a global biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases worldwide. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fu …
  • Shengli Oil and Gas Pipe Holdings Ltd：企業の戦略・SWOT・財務情報
    Shengli Oil and Gas Pipe Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Shengli Oil and Gas Pipe Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • EnBW Energie Baden-Wurttemberg AG：発電所・企業SWOT分析
    EnBW Energie Baden-Wurttemberg AG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Navitas Limited (NVT)：企業の財務・戦略的SWOT分析
    Navitas Limited (NVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • JSS Medical Research Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary JSS Medical Research Inc (JSS Medical Research) is a contract research organization that offers clinical research services. The organization provides clinical trial services in therapeutic areas such as oncology, infectious disease, cardiovascular disorders, psychiatry, neurology, respirator …
  • Abu Dhabi Commercial Bank P.J.S.C.：企業の戦略・SWOT・財務情報
    Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report Summary Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • CommScope Holding Company Inc：企業のM&A・事業提携・投資動向
    CommScope Holding Company Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CommScope Holding Company Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • International Stem Cell Corp (ISCO)：企業の財務・戦略的SWOT分析
    Summary International Stem Cell Corp (ISCC) is a clinical stage biotechnology company that develops stem cell technology solutions. The company develops parthenogenesis, a stem cell technology that improves the field of regenerative medicine. It provides stem cells such as embryonic stem cells, adul …
  • Imuraya Group Co., Ltd.：企業の戦略・SWOT・財務分析
    Imuraya Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Imuraya Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Etiqa Life and General Assurance Philippines Inc：企業の戦略・SWOT・財務分析
    Etiqa Life and General Assurance Philippines Inc - Strategy, SWOT and Corporate Finance Report Summary Etiqa Life and General Assurance Philippines Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …
  • Cold Spring Harbor Laboratory：製薬・医療：M&Aディール及び事業提携情報
    Summary Cold Spring Harbor Laboratory (CSHL) is a research and education institution that offers molecular biology and genetics services. The institution offers research services such as graduate research, research training, clinical research, quantitative biology research, postdoctoral research, di …
  • Maritz Holdings Inc.：企業の戦略的SWOT分析
    Maritz Holdings Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • First Bancorp. (FBP)：企業の財務・戦略的SWOT分析
    First Bancorp. (FBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PacifiCorp：発電所・企業SWOT分析
    PacifiCorp - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executi …
  • Shinva Medical Instrument Co Ltd (600587)-医療機器分野：企業M&A・提携分析
    Summary Shinva Medical Instrument Co., Ltd. (Shinva Medical) manufactures and markets medical instruments and environmental protection equipment for various healthcare markets. The company’s products portfolio includes sterilizers, radiotherapy equipment, digital diagnosis equipment, surgical instru …
  • TOTAL S.A.：戦略・SWOT・企業財務分析
    TOTAL S.A. - Strategy, SWOT and Corporate Finance Report Summary TOTAL S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Kansas City Power & Light Co：企業の発電所・SWOT分析2018
    Kansas City Power & Light Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • NRW Holdings Ltd：企業の戦略・SWOT・財務情報
    NRW Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary NRW Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆